K. S. Carmon

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer

This study develops and tests EREG-targeting ADCs showing efficacy in both RAS mutant and wildtype CRC, with high potency and safety in preclinical models.

An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer

This study develops an antibody-drug conjugate targeting GPR56 and shows it is effective against colorectal cancer models.

Loss of LGR5 through plasticity or gene ablation is associated with therapy resistance and enhanced MET-STAT3 signaling in colorectal cancer cells

This study shows that loss of LGR5 in colorectal cancer cells through plasticity or gene ablation activates MET-STAT3 signaling, leading to therapy resistance and suggesting new treatment strategies targeting plasticity.

Drug Conjugates of Antagonistic RSPO4 Mutant For Simultaneous Targeting of LGR4/5/6 for Cancer Treatment

This paper develops RSPO4 mutant-based peptibody drug conjugates that target LGR4/5/6, showing potent cytotoxic effects and tumor suppression in vitro and in vivo.

Chromatin State Dynamics Confers Specific Therapeutic Strategies in Enhancer Subtypes of Colorectal Cancer

This study identifies enhancer subtypes in colorectal cancer through epigenomic analysis and proposes targeted therapeutic strategies based on these subtypes.

The most common RNF43 mutant G659Vfs41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis

The paper shows that the RNF43-G659Vfs41 mutation is functional and not a driver mutation in tumorigenesis, but may be a passenger mutation in MLH1-downregulated tumors.